Skip to main content

Table 1 Patients’ characteristics

From: Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study

Characteristic Value in study sample
Number of patients 64
Male 54 (84.4%)
Age (years) 65.4 ± 14.1
Body mass index 28.5 ± 4.1
High blood pressure 34 (53.1%)
Coronary heart disease 12 (18.8%)
Peripheral arterial disease 3 (4.7%)
Stroke 7 (10.9%)
Dyslipidaemia 34 (53.1%)
Diabetes mellitus 17 (26.6%)
Chronic sleep apnoea 9 (14.1%)
Psoriasis 6 (9.4%)
Ongoing diuretic treatment 15 (23.4%)
History of renal stones 11 (17.2%)
Familial history of gout 14 (21.9%)
eGFR (CKD-EPI/MDRD) 75.6 ± 25.6
CKD 3 or worse (clearance <60 ml/min) 16 (25.0%)
Daily alcohol consumption (g) 14.5 ± 22.7
Excessive sweetened beverages 8 (12.5%)
Excessive purine-rich foods 17 (26.6%)
2015 ACR/EULAR diagnosis score 12.8 ± 2.4
Crystal-proven gout 11 (17.2%)
Clinical tophi 21 (32.8%)
Gout duration (years) 12.8 ± 12.3
Number of flares per year 4 ± 6
Ongoing urate-lowering therapy (n) 43 (67.2%)
Urate-lowering therapy  
 Febuxostat 17 (39.5%)
 Allopurinol 24 (55.8%)
 Benzbromarone 1 (2.3%)
 Probenecid 1 (2.3%)
Serum uric acid level (mg/dl) 7.36 ± 2.55
  1. Quantitative variables are expressed as mean ± standard deviation, and qualitative variables as number (percentage). eGFR estimated glomerular filtration rate, CKD chronic kidney disease, MDRD modification of diet in renal disease, ACR American College of Rheumatology, EULAR European League Against Rheumatism